Regeneron halts Phase 1/2 uveitis antibody trial over unfavorable risk-benefit profile

Regeneron has stopped a Phase 1/2 study of its anti‑inflammatory antibody REGN7041 in non‑infectious uveitis, citing an unfavorable benefit‑risk assessment.

The antibody targets CD3 on immune cells to modulate inflammation, but trial data indicated safety concerns that outweighed potential efficacy.

The termination adds to recent setbacks for Regeneron, including the Phase 3 failures of itepekimab, a Dupixent follow‑up, and a melanoma combination regimen.

REGN7041 has been removed from Regeneron’s pipeline, and the company has not disclosed further development plans for the candidate.